Cost-efficacy of 5-HT3-receptor antagonists in the treatment of acute chemotherapy-induced emesis - Health economic analysis based on recent metaanalytic results;Wirksamkeit und kosten der 5-HT3-antagonisten beim akuten chemotherapieinduzierten erbrechen: Gesundheitsokonomische analyse auf der basis aktueller metaanalytischer daten

Medizinische Klinik

Volumn 92, Issue 12, 1997, Pages 747-752

  Brüggenjürgen, Bernd ^a   Du Dois, Andreas ^b  

^a Institut für Health Economics and Disease Management   (Germany)

^b St VJncentius Krankenhaus

Author keywords

5 HT3 Antagonists; Chemotherapy; Cost efficacy analysis; Emesis; Health economics; Metoclopramide

Indexed keywords

CORTICOSTEROID; METOCLOPRAMIDE; SEROTONIN 3 RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CORTICOSTEROID THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH ECONOMICS; HUMAN; META ANALYSIS; PRESCRIPTION; TREATMENT PLANNING; VOMITING;

EMESIS;

EID: 0031463262     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044673     Document Type: Article

References (17)

1. Brüggenjürgen Iï. Pharmakoökonomie: Eine budgetübergreifende Methode zur Bewertung von Arzneimitteln. Krankenhampharmazie 1993;9:404-7.
2. Buxton MJ, O'Brien BJ. Economic evaluation ofondansetron: preliminary analysis using clinical trial data prior to price setting. BrJ Cancer 1992;66:64-7.
3. Chevalier B, Marry M, Paillarse J-M. Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles, lîrj Cancer 1994;70:1171-5.
4. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM. On the receiving end-patients perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:200-8.
5. Cox F. Ondansetron - a cost-effective advance in antiemetic therapy. Presented at the European Congress of the European Society for Medical Oncology, Lyon, France, Novembers, 1992.
6. Cunningham D, Gore M, Davidson N. The real cost of emesis - an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy forcancer. Eur J Cancer 1993;29A:303-6.
7. Dicato MA. Oral treatment with ondansetron in an outpatient setting. Eur J Cancer 1991;27:Suppl:18-9.
8. du Bois A, Meerpohl HO, Vach \V, Kommoss FG, Fenzl E, Ptleiderer A. Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron. EurJ Cancer 1992; 28:450-7.
9. du Bois A. Pathophysiologie, klinischer Verlauf und Behandlung der Chemotherapie-induzierten Emesis. In: Emesis in der Tumortherapie. Hamburg: Ellyott Medizin Verlag, (im Druck).
10. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1-5.
11. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cispbrin-induced emesis. Ann Oncol 1995;6:805-10.
12. HainsworthJ, Harvey \V, Pendergrass K. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991; 9: 721-8.
13. Konsensgruppe Gesundheitsökononiie". Empfehlungen zur gesundheîrsôkonomischen Evaluation. Z Allg Med 1996;72:483-90.
14. PIoskerGL, RichardJM. Ondansetron: a pharmacoeconomic and qiuliry-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. Pharmacoeconomics 1992:2:285-304.
15. Scherbel G, Dodenmüüer-Kroll R, Matthias M, Nielsen A, von Richthofen K-F. Antiemetische Therapîefonnen - Kosten und Effektivität im Vergleich. Arzneimitteltherapie extra 1994;17:t-8.
16. Seynaeve C, Schuller J, liuser K. Comparison of the antiemetic efficacy of different doses of ondansetron given either as a continuous infusion or as a single intravenous dose, in acute cisplacin-induced emesis -A multicentre doubleblind, randomised parallel group study. Dr J Cancer 1992;66:192-7.
17. Stewart A, McQuade lî, CronjeJDE, et al. Ondansetron compared with granhetron in the prophylaxis of cyclophasphamide-induced emesis in out-patients: A multicentre, double-blind, double-dummy, randomised, parallel-group study. Oncology-1995; 52:202-210.